Bayer Intellectual Property Gmbh

Bayer Healthcare Aktiengesellschaft

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Bayer Pharma Aktiengesellschaft

Oklahoma Medical Research Foundation

Aicuris Gmbh + Co. Kg.

Andre Rosenthal

Intermed Discovery Gmbh

Christoph Freiberg

Andreas Wilmen

Mark Trautwein

Simone Greven

Lars Linden

Axel Harrenga

Christiane Otto

Rainer Endermann

Thomas Lampe

Josef Pernerstorfer

Jens Pohlmann

Simon Holton

Uwe Gritzan

Mitsuyuki Shimada

Guido Schiffer

Nina Brunner

Frank Dittmer

Ben Newton

Sven Golfier

Dorian Schönfeld

Jörg Willuda

Julian Marius Glück

Philip Beckhove

Michael Otteneder

Yingzi Ge

Jessica Pinkert

Eva-Maria Gutierrez

Peter Nell

Niels Svenstrup

Andrea Eicker

Sandra Bruder

Siegmund Wolf

Joachim Schuhmacher

Siegfried Raddatz

Hanna Tinel

Stefan Weigand

Ji-Yun Kim

Xiao-Yan Zhao

Ulrich Haupts

Yolanda Cancho-Grande

William John Broughton

Kerstin Ehlert

Andr&eacute; Rosenthal

Xavier Philippe Perret

Xinquan Wang

Subramanian Yegneswaran

Karin Regnstrom

Ursula Egner

Kirsten Leineweber

Gutierrez Eva-Maria

Mitsuyuki 905 Laurel Court Nara Minami Shimada

Martin Michels

The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human andCEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

Anti-CEACAM6 antibodies and uses thereof

Provided are optimized humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. In particular, the antibodies bind to particular epitopes outside the catalytic triad of the active site of human activated protein C. Methods of treatment employing these antibodies are described herein.

Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof

The present invention is directed to the neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen-resistant breast cancer. The antibody of the invention blocks prolactin receptor-mediated signalling.

Neutralizing prolactin receptor antibody Mat3 and its therapeutic use

The present invention is directed to the neutralizing prolactin receptor antibody 006-H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.

Neutralizing prolactin receptor antibodies and their therapeutic use

The present invention provides Relaxin fusion polypeptides A-L-B with a non-wild type array of the Relaxin A-chain and Relaxin B-chain, wherein the A- and B-chains are connected by a linker peptide. The invention further provides Relaxin fusion polypeptides with extended half-life. Furthermore, the invention provides nucleic acid sequences encoding the foregoing fusion polypeptides, vectors containing the same, pharmaceutical compositions and medical use of such fusion polypeptides.

Relaxin fusion polypeptides and uses thereof

The neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen-resistant breast cancer. The antibody blocks prolactin receptor-mediated signalling.

The present invention is directed to the neutralizing prolactin receptor antibody 005-C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.

The invention relates to compounds of general formula (I), to a method for the production thereof, to pharmaceutical compositions containing them, and to their use in the treatment and/or prophlaxis of diseases in humans or animals, particularly bacterial infections diseases. The compounds are derivatives of the natural substances andrimide and moiramide B.

Derivatives of andrimide and moiramide B having antibacterial properties

The invention relates to antibacterial amide macrocycles and processes for their preparation, their use for the treatment and/or prophylaxis of diseases and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially bacterial infections.

Antibacterial amide macrocycles IV

The present invention relates to compounds, to processes for preparing them, to pharmaceutical compositions comprising them, and to their use in the therapy and/or prophylaxis in illnesses in people or animals, especially diseases of bacterial infection.

Cinnamic acid amides

The present invention relates to compounds, to processes for preparing them, to pharmaceutical compositions comprising them, and to their use in the therapy and/or prophylaxis of diseases in people or animals, especially diseases of bacterial infection.

Arylamides

The sequencing and analysis of the complete nucleotide sequence of symbiotic plasmid pNGR234a isolated from Rhizobium sp. NGR234. The complete sequence of pNGR234a is presented. The analysis includes the identification of a number of novel ORFs and the proteins expressible therefrom which have been ascribed putative functions.

Genomic sequence of Rhizobium sp. NGR 234 symbiotic plasmid

Growing community of inventors

Wuppertal, Germany

Christoph Freiberg